Qilu Hospital of Shandong University
Jinan, Shandong, 257000, China
NCT Number: NCT04810793
The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Observational
Jinan, Shandong, 257000, China
Helicobacter pylori (HP) infection is a common global infectious disease, which is an important cause of chronic gastritis, peptic ulcer and gastric cancer.
At present, due to the non-standard Helicobacter pylori eradication program in clinical work, poor patient compliance and other reasons, the phenomenon of HP eradication treatment failure is more and more common. However, there is still no conclusion on the most appropriate time for remedial treatment in patients with Hp eradication failure.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens
Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens
Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens
Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group
Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group
Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group
Time frame: 1year
The most suitable re-eradication time will be assessed by paired comparison method .
Shandong University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05371249
Helicobacter Pylori
New Taipei City, Taiwan
View Trial DetailsNCT06851468
Helicobacter Pylori
Lanzhou, Gansu, China
View Trial DetailsNCT05790525
Helicobacter Pylori
Xi'an, Shaanxi, China
View Trial DetailsNCT06687499
Drug Resistance, Multiple, Helicobacter Pylori
Tainan, Taiwan
View Trial Details